SINTX Technologies Provides Business Update Highlighting Strategic Focus to Medical Device Commercialization 

Rhea-AI Summary

SINTX Technologies (NASDAQ: SINT) has announced a strategic transformation from an industrial-ceramics business to a focused medical device innovator, leveraging its silicon nitride technology. The company reported $6.5 million cash on hand as of March 31, 2025, nearly doubled from $3.6 million, bolstered by a $5.0 million private placement in February 2025. SINTX has significantly reduced its operating cash burn from $2.7M to $1.3M year-over-year. The company is streamlining operations through the sale of TA&T subsidiary, shutdown of its Armor subsidiary, and lease liability negotiations. SINTX's strategic focus includes expanding silicon nitride applications in medical markets, including orthopedic implants, spinal fusion devices, dental products, and medical textiles. The company maintains the only FDA-registered and ISO 13485 certified silicon nitride ceramic manufacturing facility.

Positive

• Cash position nearly doubled to $6.5M from $3.6M
• Secured $5.0M private placement with potential for additional $5.0M from warrants
• Reduced quarterly operating cash burn by 52% to $1.3M
• Strategic divestment of non-core assets and operational streamlining
• Maintains exclusive FDA-registered and ISO 13485 certified silicon nitride facility

Negative

• Significant restructuring and workforce reduction required
• Ongoing lease liability negotiations indicating potential financial obligations
• Complete pivot from diversified business model to focused medical device strategy carries execution risks

Insights

Medical Device Industry Analyst

SINTX pivots to medical applications, doubles cash position to $6.5M, reduces cash burn, while divesting non-core assets for strategic growth.

SINTX's strategic pivot to becoming a pure-play medical device company represents a significant business transformation with promising fundamentals. The company has doubled its cash position to $6.5 million from $3.6 million at year-end, bolstered by a $5 million private placement in February. This improved financial position provides crucial runway for their transformation.

The company's focus on silicon nitride (Si₃N₄) ceramics leverages unique material properties - biocompatibility, antimicrobial capabilities, and pro-regenerative characteristics - targeting high-value applications in orthopedics, spinal fusion, dental, and medical textiles. Their strategic advantage stems from operating the only FDA-registered, ISO 13485 certified silicon nitride ceramic manufacturing facility.

Management's disciplined approach to operational efficiency is evident in their reduced cash burn - down 52% from $2.7 million to $1.3 million year-over-year. The divestiture of non-core assets (TA&T subsidiary), workforce reductions, and shuttering the underperforming Armor subsidiary demonstrate commitment to resource optimization.

The company has also strengthened governance with new board appointments and secured leadership stability through long-term employment agreements with the CEO and CIO. The potential for additional $5 million from warrant exercises at $3.32 per share provides further financial flexibility.

While SINTX faces the typical risks associated with medical device commercialization (regulatory hurdles, market adoption challenges), their targeted focus on infection resistance and tissue healing addresses significant unmet clinical needs, positioning them in attractive market segments with substantial growth potential. The company's transformation appears well-structured with tangible progress on both operational and financial fronts.

Salt Lake City, UT , May 15, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT), an advanced ceramics company pioneering medical and antipathogenic applications of silicon nitride (Si₃N₄), today provided a comprehensive update on its operational progress, strategic initiatives, and financial position for the first quarter ended March 31, 2025.

“We are executing a disciplined transformation that aligns our core capabilities in advanced ceramics with fast-growing, high-impact healthcare applications. This transition positions us for sustainable value creation,” said Eric K. Olson, CEO and President of SINTX Technologies.

Refocusing on High-Growth Medical Markets

SINTX has accelerated its transition from a diversified industrial-ceramics business to a pure-play medical device innovator. Silicon nitride’s proven biocompatibility, antimicrobial properties, and pro-regenerative properties uniquely position it for:

• Orthopedic implants
• Spinal fusion devices
• Dental products
• Medical Textiles including: wound care, surgical masks, sutures, drapes and other antipathogenic surfaces

This strategic redirection aims to address large, underserved clinical needs where infection resistance and osteogenesis and tissue healing are critical.

Technology & Market Development

Recent scientific and commercial initiatives include:

• New R&D programs targeting implantable and antipathogenic products
• An active technology pipeline focused on surgical-grade silicon nitride devices
• Partnerships and licensing discussions with leading medical OEMs
• SINTX’s Salt Lake City facility remains only FDA-registered and ISO 13485 certified, silicon nitride ceramic manufacturer

Improved Financial Position

• $6.5 million cash on hand as of March 31, 2025 – nearly doubling from $3.6 million at year-end
• Recent $5.0 million private placement in February 2025 supported strategic runway along with potential to raise an additional $5.0 million dollars from the exercise of warrants with an exercise price of $3.32 per share of common stock
• Reduced operating cash burn from $2.7M in Q1 2024 to $1.3M in Q1 2025 due to cost optimization
  
  

Operational Streamlining

• Sale of non-core subsidiary TA&T to Tethon Corporation
• Workforce reduction and shut down of underperforming Armor subsidiary
• Initiated negotiations to reduce long-term lease liabilities, particularly at the Armor facility
  
  

These actions are expected to further unlock capital for high-return growth projects.

Strengthened Governance and Leadership

In Q2, the Company welcomed a reconstituted Board of Directors with new appointments across all Board committees, reinforcing corporate oversight. In parallel, the Company entered into new long-term employment agreements with CEO Eric Olson and CIO Gregg Honigblum .

Path Forward

SINTX is now strategically aligned around:

• Expanding the use of silicon nitride in medical and antipathogenic markets
• Licensing and commercialization of proprietary technologies
• Select asset divestitures and disciplined capital investment
• Building long-term shareholder value through innovation and execution

“We are grateful for the support of our shareholders during this transformation. With a stronger balance sheet, a focused mission, and world-class technology, SINTX is well-positioned for a new era of innovation and impact in healthcare,” Olson added.

For more information, please visit www.sintx.com

About SINTX Technologies, Inc.

Located in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter into new markets. For more information on SINTX Technologies or its materials platform, visit www.sintx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy,” "future," "likely," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding our ability to create long-term value for shareholders.

Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Forward looking statements include: our transition to a medical device innovator positions us for sustainable value creation and the we are well-positioned for a new era of innovation and impact in healthcare. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulty in commercializing ceramic technologies and development of new product opportunities. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 19, 2025, and in SINTX’s other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law.

Business and Media Inquiries for SINTX:
SINTX Technologies
801.839.3502
IR@sintx.com

FAQ

What is SINTX Technologies' (SINT) new strategic focus in 2025?

SINTX is transforming from an industrial-ceramics business to a pure-play medical device innovator, focusing on silicon nitride applications in orthopedic implants, spinal fusion devices, dental products, and medical textiles.

How much cash does SINTX Technologies (SINT) have as of Q1 2025?

SINTX reported $6.5 million in cash as of March 31, 2025, nearly double from $3.6 million at year-end, supplemented by a $5.0 million private placement in February 2025.

What operational changes has SINTX Technologies (SINT) implemented in 2025?

SINTX has sold its TA&T subsidiary to Tethon Corporation, shut down its underperforming Armor subsidiary, reduced workforce, and initiated negotiations to reduce long-term lease liabilities.

How has SINTX Technologies (SINT) improved its cash burn rate?

SINTX reduced its operating cash burn from $2.7M in Q1 2024 to $1.3M in Q1 2025 through cost optimization measures.

What are the main medical applications for SINTX Technologies' (SINT) silicon nitride technology?

SINTX's silicon nitride technology is used in orthopedic implants, spinal fusion devices, dental products, and medical textiles including wound care, surgical masks, sutures, and antipathogenic surfaces.